The biopharmaceutical landscape, which has been characterized by aggressive retrenchment and workforce volatility since 2022, is showing tentative signs of…
Read More
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
The pharmaceutical and biotechnology sectors are showing tentative signs of stabilization as the aggressive downsizing trend that characterized the previous…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The biopharmaceutical industry is grappling with a profound challenge: the silent erosion of critical process knowledge, particularly "tacit knowledge," during…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The pharmaceutical industry, particularly the rapidly evolving biopharmaceutical sector, faces a silent but significant challenge: the erosion of critical "tacit…
Read More
As Cell Therapies Scale and CDMOs Cut Staff, Process Know-How Is Often Getting Lost in Tech Transfer
The biopharmaceutical industry is grappling with a critical challenge: the silent erosion of invaluable "tacit knowledge" during technology transfer processes.…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The biopharmaceutical industry, in its relentless pursuit of innovation and efficiency, faces a silent but profound challenge: the erosion of…
Read MoreYOU MAY HAVE MISSED
